In alphabetical order:
Akrivia Health
Exhibition, stand number: 3.111
Akrivia Health is an AI-based neuroscience company focused on transforming mental health and dementias research through data. We are building the world's largest real world and multi-omic dataset focused solely on mental health and dementias, and our mission is to transform research in this space by unlocking the power of these data, thus helping to alleviate the burden of one of the world’s most pressing medical needs. Established in May 2019 as a spin out of the University of Oxford, we have a 15-year history in the NHS and academia that begun in 2009.
For more information, visit www.akriviahealth.com
ALBA Network
Exhibition, stand number: 3.112
The ALBA Network, a division of FENS, was created to promote equity and diversity in the brain sciences. The goals of ALBA are to recognize implicit bias and discrimination, and to provide better visibility and professional development opportunities to scientists from underrepresented groups in brain research. This is achieved by highlighting diverse scientist profiles through a series of interviews; organizing webinars to discuss EDI issues, awards, mentoring sessions, and networking events; and providing a platform to disseminate data and best practices toward creating a more inclusive brain research community. To discover all our activities and become a member, visit https://www.alba.network/
Boehringer Ingelheim
Exhibition, stand number: 3.204
At Boehringer Ingelheim, we hope to alleviate the burden on people living with serious mental illnesses, their care partners, loved ones, and society. To do this, we have made a long-term commitment to invest in research with the aspiration of redefining mental healthcare in partnership with multiple stakeholders and innovative partners. Our ambition is to create a deeper understanding of the drivers of serious mental illnesses and to provide highly effective therapies for those living with these conditions.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com
CINP – International College of Neuropsychopharmacology
Exhibition, stand number: 3.115
The International College of Neuropsychopharmacology (CINP), founded in 1957 in Zurich, Switzerland, is a global organization connecting biologists, researchers, psychiatrists, neurologists, pharmacologists, and psychologists. It enables clinicians to stay updated on research and treatments while helping researchers address clinical challenges. As a leading society in the field, CINP actively collaborates with peer organizations and offers members access to specialized educational sessions and a mentor/mentee program. Its annual World Congress fosters interdisciplinary discussions on recent breakthroughs and developments, with a dedicated track for early-career clinicians and researchers. The congress also provides networking opportunities with global leaders in neuropsychopharmacology.
www.cinp.org
Edra by Resilience
Exhibition, stand number: 3.119
Edra is a Remote Patient Monitoring solution specifically designed for psychiatry, developed by Resilience. By combining two complementary tools, Edra provides continuous, personalized care to support patients living with depression and bipolar disorder:
- a platform for healthcare professionals, enabling them to evaluate treatment efficacy and monitor patient progress through Patient-Reported Outcomes (PROs).
- a mobile application for patients, allowing them to track their psychological and physical symptoms, and access tailored, clinically validated resources—including articles, videos, podcasts —to better manage their condition.
Resilience is a French company co-founded in 2021, dedicated to enhancing patient care by personalizing, humanizing, and optimizing the care pathway.
https://www.edra.care/en
EUFAMI
Exhibition, stand number: 3.106
EUFAMI was founded in 1992, inspired by a 1990 congress in De Haan, Belgium, where carers from across Europe shared experiences of helplessness in supporting loved ones with severe mental illness. They united to create change and support one another. Registered in Belgium as an international non-profit, EUFAMI is a democratic organisation dedicated to improving the care and welfare of those affected by mental illness. We empower member organisations to collaborate at the European level, combining efforts and sharing expertise to drive progress. We act jointly to build a better future for families and individuals impacted by mental illness.
European Brain Council (EBC)
Exhibition, stand number: 3.108
The European Brain Council (EBC) is a network of key players in the “Brain Area”, with a membership encompassing scientific societies, patient organisations, professional societies and industry partners. EBC's mission is to promote brain research with the ultimate goal of improving the lives of the millions of Europeans living with brain conditions. With the aim to speak with one voice, EBC stands as the platform to foster cooperation between its member organisations and other stakeholders, consistently promoting dialogue between scientists, industry and society.
https://www.braincouncil.eu/
European Psychiatric Association (EPA)
Exhibition, stand number: 3.114
With active individual members in as many as 88 countries and 44 National Psychiatric Association Members who represent more than 78 000 European psychiatrists, the European Psychiatric Association is the main association representing psychiatry in Europe. The EPA’s activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development. The EPA deals with psychiatry and its related disciplines and focuses on the improvement of care for the mentally ill as well as on the development of professional excellence.
FENS - The Federation of European Neuroscience Societies
Exhibition, stand number: 3.113
FENS – the Federation of European Neuroscience Societies – is the leading organisation for neuroscience in Europe. Based in Brussels, it was established in 1998 and represents 42 societies across 32 countries, bringing together over 22,000 scientists.
FENS supports its members through four key impact areas: fostering knowledge exchange, advancing neuroscience, empowering community, and investing in the future. These interconnected areas drive FENS' efforts to unite scientists, share discoveries, and provide tools and resources that benefit both the scientific community and society.
FENS supports fundamental, translational, and clinical neuroscience to deepen understanding of the brain and nervous system and works towards an inclusive, diverse, and globally connected research community.
GAMIAN-Europe
Exhibition, stand number: 3.102
The Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe) is a non-profit, patient-driven pan-European organisation that represents and advocates for the interests and rights of persons affected by mental illness. Its principal activities relate to advocacy, information, awareness-raising, education, partnership and capacity building. Overarching themes in GAMIAN- Europe's work relate to the destigmatisation of mental ill-health and the championing of patients’ rights.
https://www.gamian.eu/
GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).
H. Lundbeck A/S
Exhibition, stand number: 3.200
Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.
Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.
Neuroscience based Nomenclature (NbN)
Exhibition, stand number: 3.110
NbN goes beyond simply renaming drugs—it shifts how we conceptualize them, focusing on pharmacological mechanisms rather than indications. As psychiatry moves toward dimensional models of psychopathology rather than categorical syndromes, drug actions align more closely with pharmacology and mode of action rather than given diagnosis. To advance neurobiological understanding of brain disorders, it is important not to pigeonhole drugs for a clinical indication based on regulations, but to categorize and think of drugs according to how they engage in neurobiological mechanisms. Will present Neuroscience-based Nomenclature (NbN) for adults, children, and a special new edition for patients and families.
www.nbn.science
Neurotorium
Exhibition, stand number: 3.103
At Neurotorium.org, our mission is to improve awareness and knowledge of the brain and its diseases. We provide unbiased, freely available online educational content created for clinicians, educators, and anyone interested in learning more about the brain. Our educational material is developed, reviewed, and regularly updated by leading experts in psychiatry, neurology, and neuroscience.
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S
Exhibition, stand number: 3.201
Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Our 35,300 employees channel their passion and commitment into aiming to improve the health of our patients, with a focus in Europe on therapies in mental health, nephrology and immunology, haemato-oncology, infectious diseases and digital therapeutics.
Website: www.otsuka-europe.com
Visit us on LinkedIn @ Otsuka Pharmaceutical Companies Europe
Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.
Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.
Porsolt
Exhibition, stand number: 3.117
Porsolt is a long-established preclinical CRO fully GLP compliant.
With our Scientist-to-Scientist approach, we support you at every step of the preclinical development, providing the best scientific advice and offering tailored solutions for small Molecules, biologics, gene and cells therapies.
We have a recognized international reputation for in vitro, ex vivo, and in vivo expertise in physiopathological models, customized procedures, histology, biomarkers, and solutions for discovering treatments in over 10 different therapeutic areas.
Saladax Biomedical, Inc.
Exhibition, stand number: 3.105
Saladax Biomedical, Inc. offers rapid, precise therapeutic drug monitoring assays for psychiatric medications, for both clinical laboratories and at the point-of-care. Our MyCare™ Psychiatry assays provide quantitative insights for optimizing patient care. Revolutionizing psychiatric care, the MyCare Insite is a groundbreaking point-of-care device to measure clozapine and total aripiprazole, enabling real-time decision-making during patient consultations.
Simons Foundation
Exhibition, stand number: 3.104
Launched in 2006, the Simons Foundation Autism Research Initiative (SFARI) is a scientific initiative within the Simons Foundation’s suite of programs. SFARI’s mission is to advance the basic science of autism and related neurodevelopmental disorders. SFARI funds innovative research, promotes collaboration and open science, and develops data, tools and resources that we share with both academic and industry researchers to accelerate discovery.
Takeda Pharmaceuticals International AG
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
The Lundbeck Foundation
The Lundbeck Foundation is an enterprise foundation whose purpose is to create powerful ripple effects that bring discoveries to lives through investing actively in business and science at the frontiers of their fields.
The world’s largest brain research prize is awarded annually by the Lundbeck Foundation. Each year, they award 10 million DKK (approx. 1,3 million EUR) to one or more neuroscientists who have made a ground-breaking impact on brain research. The Brain Prize was first awarded in 2011 and has so far honoured 49 scientists from 11 different countries.
